Moderna Inc

-7.38 (-4.40%)
4:01:42 PM EDT: $160.33 +0.19 (+0.12%)
Products, Strategic Combinations

Moderna And Carisma Establish Collaboration To Develop In Vivo Engineered Chimeric Antigen Receptor Monocytes (Car-M) For Oncology

Published: 01/10/2022 11:36 GMT
Moderna Inc (MRNA) - Moderna and Carisma Establish Collaboration to Develop in Vivo Engineered Chimeric Antigen Receptor Monocytes (car-m) for Oncology.
Moderna Inc - Carisma to Receive $45 Million Up-front Cash Payment and Investment by Moderna in Form of a $35 Million Convertible Note.
Moderna Inc - Carisma Eligible to Receive Milestone and Royalty Payments.
Moderna - Carisma Will Receive Research Funding and is Eligible to Receive Development, Regulatory, and Commercial Milestone Payments, Plus Royalties.
Moderna Inc - Carisma Will Be Responsible for Discovery and Optimization of Development Candidates.
Moderna Inc - Will Lead Clinical Development and Commercialization of Therapeutics Resulting From Agreement With Carisma.
Moderna Inc - Has Option to Nominate Up to Twelve Targets for Development and Commercialization Under Carisma Agreement.